Adicet Bio, Inc.

NASDAQ:ACET

Biotechnology

Healthcare
$5.53 +0.25%

+$0.02 today

Market cap
$51.70M
Beta
1.57
P/E (TTM)
-0.8
EPS (TTM)
-$10.13
52W Low $6.01High $17.44

Volume 0.15M

Average 0.12M

ACET Deferred Revenue (Non-current)

Payments received for goods or services the company will deliver after more than one year.

Adicet Bio, Inc.NASDAQ: ACET

Deferred Revenue (Non-current) · Q1 FY2026 · quarter ended Mar 2026

Deferred revenue (non-current) remains negative

Q1 FY2026 deferred revenue (non-current) was $0, compared with $0 a year earlier.

Context

  • Deferred revenue (non-current) amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Deferred revenue (non-current) increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
Year agoMar 2025
$0— since
Deferred Revenue (Non-current) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Deferred Revenue (Non-current) history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Deferred Revenue (Non-current) vs competitors

How ACET compares with its peers on the latest reported figures

  • ACET's Mar 2026 deferred revenue (non-current) of $0 is the highest of the 8 companies compared; the peer median is $0.
  • Deferred revenue (non-current) amounts to 0.0% of total assets for ACET, versus a peer median of 0.0%.
ACET Competitors Peer median
Deferred Revenue (Non-current) for ACET and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ACETAdicet Bio, Inc.Mar 2026$0 ——0.0%
IMUXImmunic, Inc.Mar 2026$0 ——0.0%
ADAGAdagene Inc.Dec 2025$0 ——0.0%
ACRVAcrivon Therapeutics, Inc. Common StockMar 2026$0 ——0.0%
GANXGain Therapeutics, Inc.Mar 2026$0 ——0.0%
NRXPNRx Pharmaceuticals, Inc.Mar 2026$0 ——0.0%
HOWLWerewolf Therapeutics, Inc.Jun 2026$0 ——0.0%
TCRXTScan Therapeutics, Inc.Mar 2026$0 -100.0%—0.0%
Peer median (excluding ACET) $0-100.0%—0.0%

Competitors are the stored peer set for ACET. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents277.54M257.66M159.71M56.5M38.92M
Short-term Investments000119.81M119.61M
Net Receivables214K435K00342K
Inventory00000
Other Current Assets2K336K457K474K320K
Total Current Assets282.44M261.04M162.27M180.14M160.93M
Property, Plant & Equipment (Net)35M48.98M44.2M36.75M28.48M
Goodwill19.46M19.46M000
Intangible Assets00000
Long-term Investments00002.87M
Tax Assets00000
Other Non-current Assets2.04M1.21M822K3.33M76K
Total Non-current Assets56.5M69.65M45.02M40.08M31.43M
Total Assets338.94M330.69M207.3M220.22M192.36M
Account Payables3.26M4.4M2.63M4.83M4.74M
Short-term Debt00000
Tax Payables00000
Deferred Revenue4.81M0000
Other Current Liabilities4.02M5.7M6.93M7.11M5.63M
Total Current Liabilities16.32M19.71M19.29M19.39M21.53M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities115K114K130K116K62K
Total Non-current Liabilities19.49M18.65M17.83M14.22M11.61M
Total Liabilities35.81M38.35M37.12M33.61M33.15M
Common Stock4K4K4K8K10K
Retained Earnings(168.32M)(238.11M)(380.77M)(497.89M)(614.7M)
Accumulated OCI00016K102K
Other Stockholders Equity00000
Minority Interest00000
Total Equity303.13M292.34M170.18M186.61M159.21M
Total Debt20.94M21.02M20.92M17.23M14.74M
Net Debt(256.6M)(236.63M)(138.79M)(39.26M)(24.18M)

Adicet Bio, Inc.

NASDAQ:ACET

Intrinsic Alpha fair value

Locked

Current Price

$5.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.